Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this review, researchers discussed the anti-inflammatory and immunomodulatory properties of metformin and hypothesized that its topical application could benefit those with alopecia areata, given its effects on immune pathways, hair regrowth, and autoimmune disease management.

This study explored COVID-related chilblains using transcriptomics and found they showed a distinct interferon and JAK/STAT pathway activation, absent in vaccine-related chilblains, with inflammatory cell types varying over time.

Melatonin affects specific gene patterns and biological processes in goat hair growth.

This review examines targeting the JAK-STAT pathway in inflammatory skin diseases, highlighting existing JAK inhibitors and potential developments, but presents no new experimental or clinical results.

Cedrol promotes hair growth better than baricitinib by regulating immune cells.

In this study, hair follicle transcriptomic responses to a 10-day HIIT program revealed both existing and new biomarkers, such as certain miRNAs, offering a potentially effective way to monitor cellular and molecular HIIT adaptations.

This review examines clinical data on the efficacy and safety of JAK inhibitors used for immune-mediated conditions beyond rheumatoid arthritis, highlighting their potential therapeutic roles in various inflammatory diseases.

This review discusses the niches supporting adult stem cells in various organisms, including well-studied germline niches and the less understood mammalian niches, but it reports no new research findings.

This review discusses the role of the JAK-STAT pathway in autoimmune skin diseases and suggests potential therapeutic benefits of JAK inhibitors, but reports no new experimental results.

This review discusses the JAK-STAT pathway and the use of FDA-approved JAK inhibitors for autoimmune and inflammatory diseases but reports no new research findings.

In this study, researchers observed that follicular damage and stem cell loss in frontal fibrosing alopecia may be mediated by immune attacks at the bulge region, suggesting potential for JAK/STAT-targeting treatments to prevent progression.

This study suggests that statins may help treat acute alopecia areata, with animal experiments showing increased regulatory T cell populations after statin treatment in mice with the condition.

This review examines the JAK/STAT signaling pathway's significance in inflammatory skin diseases and evaluates the efficacy and safety of oral and topical JAK inhibitors for treating vitiligo and alopecia areata. Results are not reported in this study.

In this study, baricitinib improved the resolution of arthritis or rash in patients with systemic lupus erythematosus, but outcomes for skin involvement like alopecia were not reported.

This review discusses the development of Janus kinase inhibitors for dermatologic diseases and reports no new results; the authors note the need for further research on their efficacy and safety.

Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.

Stem cells compete for space using cell adhesion, and mutations can affect their competitive success, with implications for tissue health and disease.

This study found that mesenchymal stem cell treatment alleviated atopic dermatitis-like symptoms in a mouse model by modulating immune and inflammatory responses, with gene expression changes suggesting pathways for potential personalized treatment approaches.

This review discusses JAK inhibitors as promising new treatments for various chronic dermatologic conditions, including some recent drug approvals, and reports no new clinical results.

This case report discusses a successful treatment of Alopecia Areata with tofacitinib and includes a literature review on the condition's pathophysiology and the mechanism of JAK inhibitors, though it notes the high failure rate of available treatments and absence of FDA-approved options.

This study found that alopecia areata is linked to genetic factors, specifically HLA haplotypes on chromosome 6, and involves immune privilege collapse at hair follicles which is mediated by the JAK-STAT pathway and pro-inflammatory cytokines like IFN-γ.

This study explored the mechanism of Shaoyao Gancao decoction in treating alopecia areata and found that it may be closely related to the PI3K/AKT signaling pathway.

This review discusses the complex role of immune disturbances and the JAK-STAT pathway in alopecia areata, noting the success of JAK inhibitors in treatment, while highlighting ongoing debates and challenges in targeting other pathways like IL-17 and TNF-α.

In this case study, upadacitinib treatment for a patient with coexisting ulcerative colitis and alopecia universalis resulted in significant hair regrowth and maintained UC remission, suggesting potential for treating similar dual-diagnosed cases.

This review discusses current and emerging therapies for alopecia areata, highlighting unmet therapeutic needs and the psychosocial burden on patients but reports no new clinical results.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

This review summarized the latest knowledge suggesting that Janus kinase inhibitors may have therapeutic potential for treating skin diseases like atopic dermatitis and psoriasis, especially when conventional therapies do not work.

This review examines the pathophysiological mechanisms and emerging targeted treatments for alopecia areata, particularly highlighting the efficacy of oral JAK inhibitors over other less effective alternatives.

Leflunomide is more likely to help treat alopecia areata than cause it.

This meeting synopsis on the 66th Annual Montagna Symposium reports no new results but outlines discussions on precision dermatology, integrating molecular insights with clinical applications for personalized skin care.